![Joanne Euden](https://profiles-cardiff.imgix.net/attachments/683?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Joanne Euden
(hi/ei)
Timau a rolau for Joanne Euden
Cymrawd Ymchwil – Uwch Reolwr Treial
Trosolwyg
Yn Gymrawd Ymchwil yn yr Is-adran Heintiau, Llid ac Imiwnedd yn y Ganolfan Ymchwil Treialon (CTR), fi yw'r arweinydd thema ar gyfer Clefydau Heintus yn yr is-adran. Cyn trosglwyddo i ymchwil clincial, roeddwn yn ymchwilydd ôl-ddoethurol yn Sefydliad Ymchwil y Galon Cymru (WHRI) ym Mhrifysgol Caerdydd.
Mae fy niddordebau mewn Profi Pwynt Gofal (POCT) a diagnosteg clefydau heintus gyda diddordeb arbennig mewn gofal eilaidd (Meddygaeth Frys). Fodd bynnag, bydd unrhyw dreial/astudiaeth sy'n gweithio tuag at wella gofal cleifion trwy weithredu ymyriadau newydd a gwell i'r GIG yn ennyn fy niddordeb!
Mae'r treialon gweithredol rydw i'n gweithio arnynt yn cynnwys:
MIREINIO (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/refine)
EXCISE (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/excise)
PARCH (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/esteem)
EVITA (https://fundingawards.nihr.ac.uk/award/NIHR162027)
Astudiaethau blaenorol:
PRONTO (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/pronto)
EIRIN GWLANOG (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/peach)
AMDDIFFYN CYFLYM (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/rapid-protection)
ENCEPH-IG (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/enceph-ig)
Rwy'n agored i ddulliau cydweithredol ym meysydd heintiau ac imiwnedd.
Cyhoeddiad
2026
- Todd, S. et al., 2026. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Respiratory Medicine 14 (5), pp.417-431. (10.1016/S2213-2600(25)00433-3)
- Doughty, H. et al., 2026. Enhancing communication with bereaved relatives about emergency and critical care trials (ENHANCE): a mixed-methods study.. BMJ Open 16 (2) e106677. (10.1136/bmjopen-2025-106677)
2025
- Euden, J. et al. 2025. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: the PEACH mixed methods study. Health Technology Assessment 29 (52), pp.1-32. (10.3310/GGFF9393)
- Henley, J. et al. 2025. Procalcitonin to guide antibiotic use during the first wave of COVID-19 in English and Welsh hospitals: integration and triangulation of findings from quantitative and qualitative sources. BMJ Open 15 e093210. (10.1136/bmjopen-2024-093210)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
2024
- Sandoe, J. A. T. et al., 2024. A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. Journal of Antimicrobial Chemotherapy 79 (11), pp.2792-2800. dkae246. (10.1093/jac/dkae246)
- Webb, E. J. D. et al., 2024. The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. Journal of Antimicrobial Chemotherapy 79 (8), pp.1831-1842. dkae167. (10.1093/jac/dkae167)
- Webb, E. J. D. et al., 2024. Evidence of quality of life for hospitalised patients with COVID-19: a scoping review. Health Technology Assessment 29 (52), pp.33-56. (10.3310/ATPR4281)
2023
- Henley, J. et al. 2023. Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: Qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study). BMJ Open 13 (12) e077117. (10.1136/bmjopen-2023-077117)
- Little, P. et al., 2023. Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT. Health Technology Assessment 27 9. (10.3310/DGBV3199)
2022
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients (PEACH): protocol for a retrospective observational study. Methods and Protocols 5 (6) 95. (10.3390/mps5060095)
- Chatoo, S. A. et al., 2022. Antibiotic prescribing in hospitalized patients with COVID-19 as a function of inflammatory markers in wave 1 versus wave 2: a systematic review. Presented at: BSAC Spring Conference 2022 10 - 11 May 2022. Vol. 4.Vol. S.2. (10.1093/jacamr/dlac053.012)
- Euden, J. et al. 2022. PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trial. BMJ Open 12 (6) e063424. (10.1136/bmjopen-2022-063424)
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalized patients during the first wave of COVID-19: the PEACH study. Presented at: Infection 2021: BSAC Winter Conference Virtual 9-10 December 2021. Vol. 4.Vol. 1. (10.1093/jacamr/dlac004.013)
2021
- Little, P. et al., 2021. Antibiotics for lower Respiratory Tract Infection in Children presenting in Primary Care (ARTIC PC): a randomised placebo controlled trial. The Lancet 398 , pp.1417-1426. (10.1016/S0140-6736(21)01431-8)
- Powell, N. et al., 2021. Use of procalcitonin during the first wave of COVID-19 in the acute NHS hospitals: a retrospective observational study. Antibiotics 10 (5) 516. (10.3390/antibiotics10050516)
2013
- Euden, J. , Mason, S. and Williams, A. J. 2013. Functional characterization of the cardiac Ryanodine receptor pore-forming region. PLoS ONE 8 (6) e66542. (10.1371/journal.pone.0066542)
- Euden, J. et al. 2013. Investigations of the contribution of a putative glycine hinge to ryanodine receptor channel gating. Journal of Biological Chemistry 288 (23), pp.16671-16679. (10.1074/jbc.M113.465310)
2012
- Mason, S. et al. 2012. The contribution of hydrophobic residues in the pore-forming region of the ryanodine receptor channel to block by large tetraalkylammonium cations and Shaker B inactivation peptides. The Journal of General Physiology 140 (3), pp.325-339. (10.1085/jgp.201210851)
- Viero, C. et al. 2012. Techniques and methodologies to study the ryanodine receptor at the molecular, subcellular and cellular level. In: Islam, M. S. ed. Calcium Signaling. Advances in Experimental Medicine and Biology Vol. 740.Dordrecht: Springer. , pp.183-215. (10.1007/978-94-007-2888-2_8)
2010
- Carney, J. et al. 2010. The ryanodine receptor pore: Is there a consensus view?. In: Serysheva, I. I. ed. Structure and Function of Calcium Release Channels. Vol. 66, Current Topics in Membranes Elsevier Academic Press In. , pp.49-67. (10.1016/S1063-5823(10)66003-6)
2007
- Carney, J. , East, J. M. and Lee, A. G. 2007. Penetration of lipid chains into the transmembrane surface of TbMscL. Biophysical Journal 92 , pp.3556-3563. (10.1529/biophysj.106.102210)
Adrannau llyfrau
- Viero, C. et al. 2012. Techniques and methodologies to study the ryanodine receptor at the molecular, subcellular and cellular level. In: Islam, M. S. ed. Calcium Signaling. Advances in Experimental Medicine and Biology Vol. 740.Dordrecht: Springer. , pp.183-215. (10.1007/978-94-007-2888-2_8)
- Carney, J. et al. 2010. The ryanodine receptor pore: Is there a consensus view?. In: Serysheva, I. I. ed. Structure and Function of Calcium Release Channels. Vol. 66, Current Topics in Membranes Elsevier Academic Press In. , pp.49-67. (10.1016/S1063-5823(10)66003-6)
Cynadleddau
- Chatoo, S. A. et al., 2022. Antibiotic prescribing in hospitalized patients with COVID-19 as a function of inflammatory markers in wave 1 versus wave 2: a systematic review. Presented at: BSAC Spring Conference 2022 10 - 11 May 2022. Vol. 4.Vol. S.2. (10.1093/jacamr/dlac053.012)
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalized patients during the first wave of COVID-19: the PEACH study. Presented at: Infection 2021: BSAC Winter Conference Virtual 9-10 December 2021. Vol. 4.Vol. 1. (10.1093/jacamr/dlac004.013)
Erthyglau
- Todd, S. et al., 2026. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Respiratory Medicine 14 (5), pp.417-431. (10.1016/S2213-2600(25)00433-3)
- Doughty, H. et al., 2026. Enhancing communication with bereaved relatives about emergency and critical care trials (ENHANCE): a mixed-methods study.. BMJ Open 16 (2) e106677. (10.1136/bmjopen-2025-106677)
- Euden, J. et al. 2025. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: the PEACH mixed methods study. Health Technology Assessment 29 (52), pp.1-32. (10.3310/GGFF9393)
- Henley, J. et al. 2025. Procalcitonin to guide antibiotic use during the first wave of COVID-19 in English and Welsh hospitals: integration and triangulation of findings from quantitative and qualitative sources. BMJ Open 15 e093210. (10.1136/bmjopen-2024-093210)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
- Sandoe, J. A. T. et al., 2024. A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. Journal of Antimicrobial Chemotherapy 79 (11), pp.2792-2800. dkae246. (10.1093/jac/dkae246)
- Webb, E. J. D. et al., 2024. The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. Journal of Antimicrobial Chemotherapy 79 (8), pp.1831-1842. dkae167. (10.1093/jac/dkae167)
- Webb, E. J. D. et al., 2024. Evidence of quality of life for hospitalised patients with COVID-19: a scoping review. Health Technology Assessment 29 (52), pp.33-56. (10.3310/ATPR4281)
- Henley, J. et al. 2023. Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: Qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study). BMJ Open 13 (12) e077117. (10.1136/bmjopen-2023-077117)
- Little, P. et al., 2023. Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT. Health Technology Assessment 27 9. (10.3310/DGBV3199)
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients (PEACH): protocol for a retrospective observational study. Methods and Protocols 5 (6) 95. (10.3390/mps5060095)
- Euden, J. et al. 2022. PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trial. BMJ Open 12 (6) e063424. (10.1136/bmjopen-2022-063424)
- Little, P. et al., 2021. Antibiotics for lower Respiratory Tract Infection in Children presenting in Primary Care (ARTIC PC): a randomised placebo controlled trial. The Lancet 398 , pp.1417-1426. (10.1016/S0140-6736(21)01431-8)
- Powell, N. et al., 2021. Use of procalcitonin during the first wave of COVID-19 in the acute NHS hospitals: a retrospective observational study. Antibiotics 10 (5) 516. (10.3390/antibiotics10050516)
- Euden, J. , Mason, S. and Williams, A. J. 2013. Functional characterization of the cardiac Ryanodine receptor pore-forming region. PLoS ONE 8 (6) e66542. (10.1371/journal.pone.0066542)
- Euden, J. et al. 2013. Investigations of the contribution of a putative glycine hinge to ryanodine receptor channel gating. Journal of Biological Chemistry 288 (23), pp.16671-16679. (10.1074/jbc.M113.465310)
- Mason, S. et al. 2012. The contribution of hydrophobic residues in the pore-forming region of the ryanodine receptor channel to block by large tetraalkylammonium cations and Shaker B inactivation peptides. The Journal of General Physiology 140 (3), pp.325-339. (10.1085/jgp.201210851)
- Carney, J. , East, J. M. and Lee, A. G. 2007. Penetration of lipid chains into the transmembrane surface of TbMscL. Biophysical Journal 92 , pp.3556-3563. (10.1529/biophysj.106.102210)
Ymchwil
Diddordebau Ymchwil
- Heintiau, Llid ac Imiwnedd
- Sepsis
- Biofarcwyr a POCTs
- Stiwardiaeth Gwrthficrobaidd
- Meddygaeth Frys
- Dyfeisiau Meddygol
Grantiau:
2025: Cynllun Cyllid Integredig HCRW - Profion firaol anadlol wrth reoli INfants Febrile yn cyflwyno i ofal brys (REFINE): Astudiaeth beilot. (Cyd-arweinydd, arweinydd Astudiaeth CTR) £337,027)
2025: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - Hap-dreial o therapi mewnwythiennol aminophylline, magnesiwm sylffad neu salbutamol ar gyfer asthma difrifol acíwt mewn plant a phobl ifanc (EVITA) (Cyd-Ymchwilydd, Arweinydd Astudiaeth CTR) £2,359,028.40
2025: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - EXamining antibiotics for ulCerated skIn cancer Excision Surgical Excision (EXCISE) (Cyd-Ymchwilydd) £1,486,597.90
2024: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - Gwerthuso clinigol a chost-effeithiol TEstosteronE i wella ansawdd bywyd sy'n gysylltiedig â'r menopos (ESTEEM) (Cyd-Ymchwilydd, Arweinydd Astudiaeth CTR) £2,657,590.34
2023: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - Gwerthusiad ar hap o ganlyniadau clinigol gan ddefnyddio technolegau newydd i wneud y gorau o therapi gwrthficrobaidd (PROTECT), (Cyd-Ymchwilydd) £204,987
2023: Rhaglen Ymchwil NIHR er Budd Cleifion (RfPB) - Gwella cyfathrebu â pherthnasau mewn profedigaeth am dreialon brys a gofal critigol (ENHANCE) (Cyd-Brif Ymchwilydd, Arweinydd Astudiaeth CTR) £254,000
Bywgraffiad
Career Overview
2017 - date: Research Associate (Trial Manager), Division of Population Medicine, School of Medicine, Cardiff University
2007-2016: Research Associate, Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff Univeristy
2001-2003: Graduate Research Scientist, Health Protection Agency, Porton Down, Salisbury.
Education and Qualifications
2007: PhD (Biochemistry) School of Biological Sciences, University of Southampton.
'Effects of lipids on the structure of the Mechanosensitive channel, MscL'
A quantitative, lab based project using protein biochemical, biophysical and molecular biological techniques.
2001: BSc(hons) Human Biosciences, School of Biological Sciences, Plymouth University.
Modules included human genetics, applied immunology, applied toxicology, biochemistry, bacteriology & virology and cell biology.
Aelodaethau proffesiynol
Cymdeithas Cemotherapi Gwrthficrobaidd Prydain
Cynghrair GW4
UKTMN
Pwyllgorau ac adolygu
NIHR Adolygydd Cyfoed
Contact Details
+44 29225 10771
Neuadd Meirionnydd, Ystafell 708F, 7fed llawr., Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS